DiaSorin S.p.A. DIA

PLYMOUTH MEETING, Pa., September 08, 2026--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Harriss T. Currie as its Chief Financial Officer, effective September 9, 2026. Mr. Currie will assume CFO responsibilities from Jason Clemens, who will assist with the transition throu

Diasorin SpA (DSRLF) reports a 4% revenue increase in Q2 2026, driven by a U.S. immunodiagnostics recovery and strong Liaison Plex traction, while navigating China declines and tariff headwinds.

Wondering if DiaSorin at €61.66 still reflects its true worth, or if the market is missing something you can spot before others do? The share price has seen a 5.8% gain over the last 7 days, alongside declines of 10.3% over the last 30 days, 9.9% year to date, and 33.0% over the past year, so recent moves may be changing how investors think about both risk and opportunity here. Recent coverage around DiaSorin has focused on its position in the Medical Equipment space and how sentiment has...

Despite revenue growth and strategic investments, Diasorin SpA (DSRLF) faces hurdles in China and the molecular diagnostics segment.

Despite headwinds in China and Europe, Diasorin SpA (FRA:34D) reports robust core business growth and strategic advancements in the US market.

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "DiaSorin S.p.A. (DIA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. DiaSorin's immunodiagnostic and molecular diagnostics offerings are integral for the diagnosis of conditions ranging from infectious and gastrointestinal diseases to bone, mineral, and endocrine disorders, including oncology, hypertension, autoimmune, neurological, and cardiac diseases. The company effectively markets its products thr